Defunct Company
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
79
NCT05001282
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
Phase: Phase 1/2
Role: Lead Sponsor
Start: Sep 13, 2021
Completion: Jun 7, 2024
NCT05622591
ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML
Phase: Phase 1
Start: Jun 7, 2024